(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 14.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Genmab A's revenue in 2025 is $3,317,340,000.On average, 6 Wall Street analysts forecast GMAB's revenue for 2025 to be $230,772,154,005, with the lowest GMAB revenue forecast at $228,777,341,631, and the highest GMAB revenue forecast at $235,895,191,958. On average, 7 Wall Street analysts forecast GMAB's revenue for 2026 to be $276,370,174,961, with the lowest GMAB revenue forecast at $251,163,904,410, and the highest GMAB revenue forecast at $295,287,917,226.
In 2027, GMAB is forecast to generate $319,352,306,210 in revenue, with the lowest revenue forecast at $286,192,127,094 and the highest revenue forecast at $339,494,689,030.